112 related articles for article (PubMed ID: 36412431)
1. Is hypermethylation of SOX1 gene an independent prognostic marker in surgically resected non-small cell lung cancer?
Kontic M; Jovanovic D; Kern I; Nelson HH; Bojic S; Ognjanovic M; Ognjanovic S
J Cancer Res Ther; 2022; 18(6):1692-1696. PubMed ID: 36412431
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
6. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
7. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
[TBL] [Abstract][Full Text] [Related]
8. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
J Natl Cancer Inst; 2000 Sep; 92(18):1511-6. PubMed ID: 10995806
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
[TBL] [Abstract][Full Text] [Related]
11. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
12. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
Li N; Li X; Li S; Zhou S; Zhou Q
Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of SOX1 promotes cell migration in lung cancer.
Li N; Li S
Tumour Biol; 2015 Jun; 36(6):4603-10. PubMed ID: 25613070
[TBL] [Abstract][Full Text] [Related]
15. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.
Drilon A; Sugita H; Sima CS; Zauderer M; Rudin CM; Kris MG; Rusch VW; Azzoli CG
J Thorac Oncol; 2014 Sep; 9(9):1272-7. PubMed ID: 25122424
[TBL] [Abstract][Full Text] [Related]
17. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Katayama H; Hiraki A; Fujiwara K; Matsuo K; Maeda T; Chikamori K; Kishino D; Tajima K; Ueoka H; Aoe K
Asian Pac J Cancer Prev; 2007; 8(2):221-4. PubMed ID: 17696735
[TBL] [Abstract][Full Text] [Related]
19. [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].
Tang Y; Wu F; Hu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 36(7):650-4. PubMed ID: 21873791
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]